ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

evolocumab

Also written as “Evolocumab”, “Evolocumab AI/pen” and “Evolocumab Drug Substance A (Test)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia, led by 4 companies.

Drug pageEvolocumab: every studyAll 108 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 3, 201845 company-led studies, 2 open or runningNext primary completion: May 29, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only422 open or runningphase 4since Jan 3, 2018May 27, 2010May 29, 2027phase 4 · NCT05284747
ECRI bvits history only10 open or runningphase 4since Feb 12, 2019Feb 12, 2019none ahead
Hamad Medicalits history only10 open or runningphase 4since Oct 10, 2022Oct 10, 2022none ahead
Hoffmann-La Roche10 open or runningphase 2since Nov 7, 2017Nov 7, 2017none ahead

Also a collaborator on its studies: GE Healthcare and HeartFlow.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03337698 · 314 enrolled · United States, Australia, France and more

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SYH2053ruleCSPC Pharmaceutical Groupphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedOct 14, 2025314

How it is read

Names in the registry

  • “Evolocumab”, 39 entries
  • “evolocumab”, 2 entries
  • “Evolocumab AI/pen”, 2 entries
  • “Evolocumab Drug Substance A (Test)”, 1 entry
  • “Evolocumab Drug Substance B (Reference)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.